“…It also adds to the existing literature of CRT in OHTx patients. 3,4 In the HTx population, LV systolic dysfunction and heart failure often relates to severe CAV, which portends a poor prognosis and confers a high risk of sudden death. 7,8 The use of angiotensin-converting enzyme inhibitors, -blockers, and implantable defibrillators remains largely empiric in these patients, and consideration for repeat HTx has historically been the only viable option.…”